explore -WSS

explore

author：entertainment 2025-09-27 09:45:13 - browse：8

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Second House panel advances two

hotspot

WSS

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

HIV drugs protect against transmission, even in unprotected sex

Cord blood banking comes at a high cost to babies

Helping hospitals and community health centers plan for resilience

See how much Covid

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

leisure time

explore

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Criminal prosecution for violating HIPAA: an emerging threat

New air purifier tech could be key to improving indoor air quality

Solving academic medical centers' existential crisis

Drug repurposing or repositioning? The language matters

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

BioMarin wins approval for gene therapy to treat hemophilia A

With trial win, GSK could get blood cancer drug back on market

Drug repurposing or repositioning? The language matters

Cord blood banking comes at a high cost to babies

explore

Cytokinetics CEO stresses company can launch heart drug on its own

Readers respond to H5N1 and livestock movements, and more

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Criminal prosecution for violating HIPAA: an emerging threat

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Helping hospitals and community health centers plan for resilience

hotspot

hotspot

focus

leisure time